PA
NRIX icon

Parallel Advisors’s Nurix Therapeutics NRIX Stock Holding History

Parallel Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30
Closed -$266 – 3478
2023
Q1 		$266 Hold
30
– – ﹤0.01% 3246
2022
Q4 		$329 Hold
30
– – ﹤0.01% 3112
2022
Q3 		$0 Hold
30
– – ﹤0.01% 3377
2022
Q2 		$0 Buy
+30
New +$340 ﹤0.01% 3234
2022
Q1 		– Sell
-9
Closed – – 3169
2021
Q4 		$0 Buy
+9
New +$273 ﹤0.01% 3221

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Parallel Advisors's NRIX Position: Q2 2023 in Review

Parallel Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2023, closing a stake of 30 shares — an estimated $266 sold.

Parallel Advisors first reported a position in NRIX in Q4 2021 and held it in 5 quarters. The position peaked at $329 in Q4 2022. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

  • Parallel Advisors reported no remaining Nurix Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallel Advisors sold 30 Nurix Therapeutics shares in Q2 2023, an estimated $266.
  • Parallel Advisors first reported a position in Nurix Therapeutics in Q4 2021 and held it in 5 quarters.
  • Parallel Advisors's Nurix Therapeutics position peaked at $329 in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.